Chengming Zhu

Dr. Chengming Zhu


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Theranostics
Verified
Journal Article
Open access
QLQiji Li
Qiji Li
MWMin Wang
Min Wang
YHYanqing Hu
Yanqing Hu
EZEnsi Zhao
Ensi Zhao
JLJun Li
Jun Li
LYLiping Ye
Liping Ye
Rationale: Resistance to androgen-deprivation therapy (ADT) associated with metastatic progression remains a challenging clinical task in prostate cancer (PCa) treatment. Current targeted therapies for castration-resistant prostate cancer (CRPC) are not durable. The exact molecular mechanisms mediating resistance to castration therapy that lead to CRPC progression remain obscure.

20 June 2024 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
JOJing Ouyang
Jing Ouyang
SHShuang Hu
Shuang Hu
QZQingqing Zhu
Qingqing Zhu
CLChenxin Li
Chenxin Li
TKTingting Kang
Tingting Kang
CZChengming Zhu
Chengming Zhu
TNF receptor superfamily member 11a (TNFRSF11a, RANK) and its ligand TNF superfamily member 11 (TNFRSF11, RANKL) are overexpressed in many malignancies. However, the clinical importance of RANKL/RANK in colorectal cancer (CRC) is mainly unknown. We examined CRC samples and found that RANKL/RANK was elevated in CRC tissues compared with nearby normal tissues. A higher RANKL/RANK expression was associated with a worse survival rate. Furthermore, RANKL was mostly produced by regulatory T cells (Tregs), which were able to promote CRC advancement. Overexpression of RANK or addition of RANKL significantly increased the stemness and migration of CRC cells. Furthermore, RANKL/RANK signaling stimulated C-C motif chemokine ligand 20 (CCL20) production by CRC cells, leading to Treg recruitment and boosting tumor stemness and malignant progression. This recruitment process was accomplished by CCL20–CCR6 interaction, demonstrating a connection between CRC cells and immune cells. These findings suggest an important role of RANKL/RANK in CRC progression, offering a potential target for CRC prevention and therapy.

22 February 2022 in Journal of Nanobiotechnology
Verified
Journal Article
Open access
PDF file
XHXiuyu Huang
Xiuyu Huang
MQMiaojuan Qiu
Miaojuan Qiu
TWTianqi Wang
Tianqi Wang
BLBinbin Li
Binbin Li
SZShiqiang Zhang
Shiqiang Zhang
JZJing Zhao
Jing Zhao
Background: Ovarian cancer is the most lethal gynecological cancer which is characterized by extensive peritoneal implantation metastasis and malignant ascites. Despite advances in diagnosis and treatment in recent years, the five-year survival rate is only 25–30%. Therefore, developing multifunctional nanomedicine with abilities of promoting apoptosis and inhibiting migration on tumor cells would be a promising strategy to improve the antitumor effect.Methods and results: In this study, we developed a novel ACaT nanomedicine composed of alendronate, calcium ions and cyclin-dependent kinase 7 (CDK7) inhibitor THZ1. With the average size of 164 nm and zeta potential of 12.4 mV, the spherical ACaT nanoparticles were selectively internalized by tumor cells and effectively accumulated in the tumor site. Results of RNA-sequencing and in vitro experiments showed that ACaT promoted tumor cell apoptosis and inhibited tumor cell migration by arresting the cell cycle, increasing ROS and affecting calcium homeostasis. Weekly intraperitoneally administered of ACaT for 8 cycles significantly inhibited the growth of tumor and prolonged the survival of intraperitoneal xenograft mice.Conclusion: In summary, this study presents a new self-assembly nanomedicine with favorable tumor targeting, antitumor activity and good biocompatibility, providing a novel therapeutic strategy for advanced ovarian cancer.Graphical

1 April 2021 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
QLQian Liang
Qian Liang
YWYun Wang
Yun Wang
YLYingsi Lu
Yingsi Lu
QZQingqing Zhu
Qingqing Zhu
WXWenlin Xie
Wenlin Xie
CZChengming Zhu
Chengming Zhu
The tumor necrosis factor (TNF) receptor superfamily member 11a (TNFRSF11a, also known as RANK) was demonstrated to play an important role in tumor metastasis. However, the specific function of RANK in colorectal cancer (CRC) metastasis and the underlying mechanism are unknown. In this study, we found that RANK expression was markedly upregulated in CRC tissues compared with that in matched noncancerous tissues. Increased RANK expression correlated positively with metastasis, higher TNM stage, and worse prognosis in patients with CRC. Overexpression of RANK promoted CRC cell metastasis in vitro and in vivo, while knockdown of RANK decreased cell migration and invasion. Mechanistically, RANK overexpression significantly upregulated the expression of tartrate-resistant acid phosphatase 5 (TRAP/ACP5) in CRC cells. Silencing of ACP5 in RANK-overexpressing CRC cells attenuated RANK-induced migration and invasion, whereas overexpression of ACP5 increased the migration and invasion of RANK-silencing cells. The ACP5 expression was transcriptionally regulated by calcineurin/nuclear factor of activated T cells c1 (NFATC1) axis. The inhibition of calcineurin/NFATC1 significantly decreased ACP5 expression, and attenuated RANK-induced cell migration and invasion. Furthermore, RANK induced phospholipase C-gamma (PLCγ)-mediated inositol-1,4,5-trisphosphate receptor (IP3R) axis and stromal interaction molecule 1 (STIM1) to evoke calcium (Ca2+) oscillation. The RANK-mediated intracellular Ca2+ mobilization stimulated calcineurin to dephosphorylate NFATC1 and induce NFATC1 nuclear translocation. Both blockage of PLCγ-IP3R axis and STIM1 rescued RANK-induced NFATC1 nuclear translocation, ACP5 expression, and cell metastasis. Our study revealed the functional expression of RANK in human CRC cells and demonstrated that RANK induced the Ca2+-calcineurin/NFATC1-ACP5 axis in the regulation of CRC metastasis, that might be amenable to therapeutic targeting.

1 November 2021 in Cancer Letters
Verified
Journal Article
Closed access
YWYun Wang
Yun Wang
QLQian Liang
Qian Liang
KLKefeng Lei
Kefeng Lei
QZQingqing Zhu
Qingqing Zhu
DZDelong Zeng
Delong Zeng
CZChengming Zhu
Chengming Zhu

17 April 2023 in International Immunopharmacology
Verified
Journal Article
Closed access
XXXiaoyu Xu
Xiaoyu Xu
SYSongcheng Yin
Songcheng Yin
YWYun Wang
Yun Wang
QZQingqing Zhu
Qingqing Zhu
GZGuoxing Zheng
Guoxing Zheng
CZChengming Zhu
Chengming Zhu